Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Castellano

Showing results (201-210 of 266) with videos related to

Pageof 27
Sort By:
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Oncotarget|April 21, 2017
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinomaJavier Puente, Nuria Laínez, Marta Dueñas, et al.
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Cancers|January 21, 2022
Genomic Landscape of Vinflunine Response in Metastatic Urothelial CancerAlejandra Bernardini, Marta Dueñas, María Cruz Martín-Soberon, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
Plos One|January 30, 2014
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinomaCelia Prior, Jose Luis Perez-Gracia, Jesus Garcia-Donas, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Pageof 27

Showing results (201-210 of 266) with videos related to

Sort By:
Pageof 27
Lancet (London, England)|December 23, 2017
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Ignacio Durán, Michiel S van der Heijden, et al.
Oncotarget|April 21, 2017
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinomaJavier Puente, Nuria Laínez, Marta Dueñas, et al.
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Cancers|January 21, 2022
Genomic Landscape of Vinflunine Response in Metastatic Urothelial CancerAlejandra Bernardini, Marta Dueñas, María Cruz Martín-Soberon, et al.
Cancer|April 6, 2022
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinomaRobert J Motzer, David F McDermott, Bernard Escudier, et al.
Plos One|January 30, 2014
Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinomaCelia Prior, Jose Luis Perez-Gracia, Jesus Garcia-Donas, et al.
Nature Medicine|June 20, 2020
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature Medicine|November 6, 2019
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trialThomas Powles, Mark Kockx, Alejo Rodriguez-Vida, et al.
Nature|June 17, 2021
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Zoe June Assaf, Nicole Davarpanah, et al.
The Lancet. Oncology|December 25, 2025
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trialKarim Fizazi, Fred Saad, Teresa Alonso-Gordoa, et al.
Pageof 27